Apatinib, an oral receptor TKI that specifically targets vascular endothelial growth factor receptor 2 (VEGFR2), has been shown to inhibit the angiogenesis of tumors by prohibiting VEGF-promoted tumor development [82]. This evidence concerns the gene KDR and neoplasm.